The California Institute for Regenerative Medicine (CIRM) has endorsed the RAPID Rare Disease Funding Program.[1] The program is called Rare Disease Acceleration through Platform Innovation and Delivery.[1] It aims to create a scalable model to rapidly deliver transformative platform genetic therapies to patients with rare diseases.[1] CIRM will not only be a provider of finance, but also an active partner, providing internal resources and using a network of contacts.[1] The program supports activities in the pre-IND and IND-enabling stages for RAPID Innovation and in the IND-enabling and clinical stages for RAPID Validation.[1] It is a platform approach that reduces development costs for individual indications and accelerates the approval of therapies.[1] The program is annual until funds are exhausted.[1]